1.1. Поддубная И.В. Неходжкинские лимфомы. Клиническая онкогематология. Под ред. М.А.Волковой. М.: Медицина. 2007; 35: 724-70.2.2. Бабичева Л.Г. Значение прогностических факторов при лечении больных диффузной крупноклеточной В-клеточной лимфомой антрациклинсодержащими режимами химиотерапии. Автореф. дис. ... канд. мед. наук. 2005.3.3. Сотникова О.П. Редкие формы экстранодальных неходжкинских лимфом. Автореф. дис. ... канд. мед. наук. 2012.4.4. Zucca E, Cavalli F. Extranodal lymphomas. Ann Oncol 2000; 11 (Suppl. 3): 219-22.5.5. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas, part 1. Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997; 8: 727-37.6.6. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas, part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999; 10: 1023-33.7.7. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1992; 29: 252-60.8.8. Otter R, Gerrits W, Sandt M et al. Primary extranodal and nodal non-Hodgkin's lymphoma: A survey of a population-based registry. Eur J Cancer Clin Oncol 1989; 25: 1203-10.9.9. Rudders RA, Ross ME, DeLellis RA. Primary extranodal lymphoma: Response to treatment and factors influencing prognosis. Cancer 1978; 42: 406-16.10.10. Talaulikar D, Shadbolt B, Dahlstrom JE et al. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). J Hematol Oncol 2009; 22: 2-49.11.11. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109 (5): 1857-61.12.12. Advani RH, Chen H, Habermann TM et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010; 151 (2): 143-51.13.13. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. WHO Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press 2001; p. 171-4.14.14. Pileri SA, Dirnhofer S, Went Ph et al. Diffuse large B-cell lymphoma: One or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002; 41: 482-509.15.15. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.16.16. Ковригина А.М. Морфоиммуногистохимическая диагностика как основа диагноза лимфомы. Вместе против рака. Врачам всех специальностей. М., 2006; 2.17.17. Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 2008; 22 (5): 941-52.18.18. Colomo L, López-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 736-47.19.19. Muris JJ, Ylstra B, Cillessen SA et al. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol 2007; 136 (1): 38-47.20.20. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15 (17): 5494-502.21.21. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24 (6): 995-1007.22.22. Rosenwald A, Wrights G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.23.23. Visco C, Li Y, Xu-Monette ZY et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; p. 1-11; doi: 10.1038/leu.2012.83.24.24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.25.25. Вихрева П.Н., Шепелев М.В., Коробко Е.В., Коробко И.В. Свойства и функции супрессора опухолевого роста Pdcd4 и возможности их использования в онкологии. Мол. генет. микробиол. вирусол. 2010; 2: 3-11.26.26. Hilliard А, Hilliard B, Zheng SJ et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death. J Immunol 2006; 177 (11): 8095-102.27.27. Carayol N, Katsoulidis E, Sassano A et al. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem 2008; 283 (13): 8601-10.28.28. Miller TP, Grogan TM, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.29.29. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24 (6): 995-1007.30.30. Jerkeman M, Anderson H, Dictor M et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. Ann Hematol 2004; 83 (7): 414-9.31.31. Hoeller S, Schneider A, Haralambieva E. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 2010; 57 (1): 73-80.